Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subsetYuichiro Ohe, Kazuhiko Nakagawa, Naoyuki Nogami et al.|Japanese Journal of Clinical Oncology|2018Cited by 153